Program Content
Introduction
This continuing education activity is provided through a collaboration between SEI-Healthcare and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, nurses, and pharmacists. A statement of participation is available for other attendees.
Faculty
![](https://my-ime.com/wp-content/uploads/2024/01/peter-vs-robert.jpg)
PETER ROSSING, MD, DMSC, Clinical Professor – Department of Clinical Medicine, University of Copenhagen, Denmark
ROBERT PROVENZANO, MD, FACP, FASN Clinical Professor of Medicine, Wayne State University School of Medicine, Detroit, MI, USA
Educational needs and learning objectives
The goal of this activity is to increase HCP knowledge and competency in evidence-based diagnosis and treatment strategies for adolescents with migraine, with a focus on the use of neuromodulation devices.
Learning objectives
After completing this educational activity, learners should be able to:
- Define the complex pathophysiology of CKD progression in patients with T2D.
- Adopt the recommended screening guidelines for early diagnosis of CKD.
- Outline the pharmacologic therapies available to treat CKD in patients with T2D.
- Discuss custom therapeutic alternatives for T2D patients with CKD.
- Identify the residual risk of cardio-renal events in patients on CKD standard of care.
- Outline emergent therapies for CKD-T2D.
- Differentiate between steroidal and selective non-steroidal mineralocorticoid receptor antagonists.
- Minimize the risk of hyperkalemia when using selective non-steroidal mineralocorticoid receptor antagonists in patients with CKD and T2D.
Target Audience
This activity is intended for HCPs practicing in the US.
Enduring Materials CE Activity
Release Date: June 30, 2023
Expiration Date: June 30, 2024
This activity is no longer offering credit.
Disclosures
Faculty disclosures
Professor Robert Provenzano is member of the board for Nephroceuticals and Vasc Alert.
Professor Peter Rossing is a consultant for Bayer, Astrazeneca, Novo Nordisk, Boehringer Ingelheim, Gilead, Abbott, Vifte and Sanofi.
Mitigation of Relevant Financial Relationships
All relevant financial relationships have been mitigated prior to the launch of this program to participants. Conflict of interest for Professors Robert Provenzano and Peter Rossing was resolved through peer review of content by a non-conflicted reviewer.
Physicians
![]() | This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and SEI-Healthcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians. |
AffinityCE designates this enduring materials activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
![]() | This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and SEI-Healthcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians. |
AffinityCE designates this enduring materials activity for a maximum of 1 AMA PRA Category 1 Credit™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
![]() | This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and SEI-Healthcare. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians. |
AffinityCE designates this enduring materials activity for a maximum of 1 AMA PRA Category 1 Credit™. Nurse Practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
![]() | Continuing Nursing Education is provided for this activity through the joint providership of AffinityCE and SEI-Healthcare. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides 1.0 contact hour of continuing nursing education credit. |
Pharmacists
![]() | AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This knowledge-based CPE activity will provide 1.0 contact hour for participants. There is no cost to participate. Participant CE records will be electronically communicated to CPE Monitor. UAN: 0829-9999-23-XXX-L01 |
Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
Commercial Support
Educational Support for this activity was provided by Bayer AG.
Participation Costs
There is no cost to participate in this CE activity.
CME Inquiries
For all CME policy-related inquiries, please contact us at [email protected]
How to Earn CE Credit
Physicians, Physician Assistants, Nurse Practitioners, Nurses
1. Go to the following web site: https://my-ime.com
2. Register or enter your profile ID.
3. Complete the activity. The certificate will be available to you.
Pharmacists
1. Go to the following website (click here)
2. Login and enter your eProfile ID.
3. Your Pharmacy CE records will be electronically communicated to CPE Monitor.
![](https://my-ime.com/wp-content/uploads/2024/01/shutterstock_2223864519.jpg-background-portal-1-1024x630.jpg)
1) Szperka C. Continuum (Minneap Minn). 2021;27(3):703–31.
2) Gibler RC, et al. Pediatric Health Med Ther. 2022;13:309–23.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.